Mirabegron
- Generic Name
- Mirabegron
- Brand Names
- Myrbetriq, Betmiga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24N4O2S
- CAS Number
- 223673-61-8
- Unique Ingredient Identifier
- MVR3JL3B2V
- Background
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
- Indication
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 236
- Registration Number
- NCT06551246
- Locations
- 🇩🇰
Department of Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Aarhus N, Denmark
🇩🇰Department of Pediatric and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Pediatric and Adolescent medicine, Esbjerg Hospital, Esbjerg, Denmark
Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 216
- Registration Number
- NCT06465576
- Locations
- 🇩🇰
Department of Pediatric and Adolescent medicine, Esbjerg Hospital, Esbjerg, Denmark
🇩🇰Department of Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Aarhus N, Denmark
🇩🇰Department of Pediatric and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark
Management of OAB in Female Patients .
- Conditions
- Interventions
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Elsayed Abdelhalim Elsayed
- Target Recruit Count
- 300
- Registration Number
- NCT06184334
- Locations
- 🇪🇬
Kafrelsheikh University hospital, Kafr Ash Shaykh, Egypt
MIrabegron and Physiological Function in Cold Environments
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 17
- Registration Number
- NCT05990387
- Locations
- 🇺🇸
Indiana University, Bloomington, Indiana, United States
Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05946902
- Locations
- 🇨🇳
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan
Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 48
- Registration Number
- NCT05880862
- Locations
- 🇺🇸
University of Texas Medical Branch at Galveston, Galveston, Texas, United States
Effect of Mirabegron on Promoting Brown Adipose Tissue Activation
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05779514
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 60
- Registration Number
- NCT05713799
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
ADRB3 Signaling Pathway in Human Adipose Tissue
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 40
- Registration Number
- NCT05634174
- Locations
- 🇺🇸
UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05621616
- Locations
- 🇧🇪
Site BE32001, Edegem, Belgium
🇹🇷Site TR90002, Ankara, Turkey
🇹🇷Site TR90001, Mersin, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.